ST PHARM revenue for the last year amounted to 284.10 B KRW, the most of which — 251.56 B KRW — came from its highest performing source at the moment, Raw Drug, the year earlier bringing 209.27 B KRW. The greatest contribution to the revenue figure was made by Switzerland — last year it brought ST PHARM 98.64 B KRW, and the year before that — 110.25 B KRW.